ARTICLE | Company News
Epigenomics genomics, diagnostic news
August 15, 2011 7:00 AM UTC
Epigenomics will restructure and reduce headcount by about 39 (46%) to 45 and will discontinue early stage research to focus on the U.S. market. Details on the cuts were not disclosed. Epigenomics said it is preparing for the U.S. launch of its second-generation colorectal cancer test Epi proColon 2.0, for which a PMA submission is slated next quarter. ...